.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Fuji
Teva
Dow
Johnson and Johnson
Cerilliant
Mallinckrodt
Daiichi Sankyo
US Department of Justice
Express Scripts

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,723,910

« Back to Dashboard

Which drugs does patent 7,723,910 protect, and when does it expire?


Patent 7,723,910 protects LEVULAN and is included in one NDA.

This patent has twenty-eight patent family members in twenty countries.

Summary for Patent: 7,723,910

Title:Method of photodynamically diagnosing or treating a contoured surface
Abstract:A method of photodynamically diagnosing or treating a contoured surface includes topically applying 5-aminolevulinic acid to the contoured surface and irradiating the contoured surface with substantially uniform intensity visible light from a plurality of light sources generally conforming to the contoured surface. The plurality of light sources may comprise fluorescent tubes.
Inventor(s): Lundahl; Scott (Lexington, MA), Kozodoy; Rebecca (Randolph, MA), Carroll; Ronald (Hingham, MA), Leppelmeier; Elton (Highland Height, OH)
Assignee: DUSA Pharmaceuticals, Inc. (Wilmington, DE)
Application Number:11/716,014
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
DusaLEVULANaminolevulinic acid hydrochlorideSOLUTION;TOPICAL020965-001Dec 3, 1999RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,723,910

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,723,991Illuminator for photodynamic therapy► Subscribe
6,223,071 Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light► Subscribe
8,758,418Illuminator for photodynamic therapy► Subscribe
8,030,836Illuminator for photodynamic therapy► Subscribe
8,216,289Illuminator for photodynamic therapy► Subscribe
7,190,109Illuminator for photodynamic therapy► Subscribe
6,709,446 Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,723,910

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland344106► Subscribe
Poland192844► Subscribe
New Zealand507891► Subscribe
Turkey200003233► Subscribe
Norway328315► Subscribe
Portugal1075315► Subscribe
Norway20005342► Subscribe
Japan4837826► Subscribe
Japan2002513660► Subscribe
Israel139397► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Johnson and Johnson
Argus Health
Medtronic
Express Scripts
Citi
Teva
Queensland Health
Cerilliant
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot